Fig. 3From: The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trialsForest plots of the OS for additional anti-EGFR target agents on mCRC (p = 0.188)Back to article page